We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.175 | 9.25 | 9.85 | - | 25,482 | 09:35:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -6.46 | 53.54M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/11/2021 14:41 | new covid virus- everything is clobbered | ali47fish | |
26/11/2021 09:56 | Don’t know the cause of the big drop but I bought some more at 41.45p | volsung | |
26/10/2021 19:00 | I know a lot of today's presentation was about the new RNAI platform but I was quite surprised hardly any mention was made of the other collaborations apart from Galapagos, especially the Wuxi-Apptec one looking at Covid-19, it doesn't even get a line in the interim results. Anyone know why not and what's happening with it? | 1347 | |
26/10/2021 18:51 | gn got it many thanks | ali47fish | |
26/10/2021 18:27 | ali47fish: the presentation is via investormeetcompany. | gnnmartin | |
26/10/2021 18:25 | ceo adding a good chunk today | ali47fish | |
26/10/2021 07:34 | I'm not sure 500k revs on a 180m market cap is fantastic but we'll see how the market reacts..! | dplewis1 | |
26/10/2021 07:29 | excellent results | ali47fish | |
25/10/2021 14:44 | etx reports tomorrow and and a presentation- anyone knows hoot access the latter please | ali47fish | |
20/10/2021 20:06 | No need to be rude | alloa2003 | |
19/10/2021 08:44 | Get some manners 'fella', and some glasses - I said 'clinical trials', they are not the same as 'in vivo characterisation studies'. | 1347 | |
18/10/2021 22:36 | "We expect to present data from our RNAi platform in our Interim Results announcement on Tuesday 26 October, when the in vivo characterisation studies will have been completed." | alloa2003 | |
18/10/2021 21:40 | Do some research fella | come2papa | |
18/10/2021 19:51 | Not aware ETX are running any clinical trails themselves are they, do you have a CT reference? Of course those using their platform(s) may be but not sure what may be imminent on that front. | 1347 | |
18/10/2021 15:43 | Did they not say they are currently doing a trial and the results should be ready for results day? | alloa2003 | |
18/10/2021 14:26 | This recent rise is still a bit baffling, I know they have some good platforms and IPR etc. but there's been nothing concrete about anything that I see to justify the recent rise, especially since they had a placing not long ago. I can only assume someone is accumulating as they know something I don't. | 1347 | |
18/10/2021 14:17 | A wee nudge higher to b/o | volsung | |
17/10/2021 21:26 | Nice recovery at the end | alloa2003 | |
11/10/2021 08:38 | Just topped up | alloa2003 | |
11/10/2021 07:42 | I may be slightly biased but why would a company focus on these studies if they didnt think they would have something positive to say to the City? | alloa2003 | |
11/10/2021 07:30 | Results due Tuesday 26 October 2021. Patent applications and trial results due with resuts. All starting to come together.... "We expect to present data from our RNAi platform in our Interim Results announcement on Tuesday 26 October, when the in vivo characterisation studies will have been completed." | alloa2003 | |
06/10/2021 16:44 | POLX FDA non-approval decision didnt go down well with biotechs. | alloa2003 | |
06/10/2021 11:42 | Bought a few more on the dip for 32.5p | volsung | |
06/10/2021 10:38 | Thats quite a steep drop this morning with nothing I can find to explain it. Anyone got any ideas? | alloa2003 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions